PHIO
Price
$2.19
Change
+$0.14 (+6.86%)
Updated
Apr 24, 02:43 PM (EDT)
Capitalization
11.99M
SLRX
Price
$0.75
Change
+$0.03 (+4.17%)
Updated
Apr 24, 02:28 PM (EDT)
Capitalization
1.14M
Ad is loading...

PHIO vs SLRX

Header iconPHIO vs SLRX Comparison
Open Charts PHIO vs SLRXBanner chart's image
Phio Pharmaceuticals
Price$2.19
Change+$0.14 (+6.86%)
Volume$173
Capitalization11.99M
Salarius Pharmaceuticals
Price$0.75
Change+$0.03 (+4.17%)
Volume$100
Capitalization1.14M
PHIO vs SLRX Comparison Chart
Loading...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHIO vs. SLRX commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHIO is a Buy and SLRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (PHIO: $2.05 vs. SLRX: $0.72)
Brand notoriety: PHIO and SLRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHIO: 25% vs. SLRX: 16%
Market capitalization -- PHIO: $11.99M vs. SLRX: $1.14M
PHIO [@Biotechnology] is valued at $11.99M. SLRX’s [@Biotechnology] market capitalization is $1.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHIO’s FA Score shows that 0 FA rating(s) are green whileSLRX’s FA Score has 1 green FA rating(s).

  • PHIO’s FA Score: 0 green, 5 red.
  • SLRX’s FA Score: 1 green, 4 red.
According to our system of comparison, PHIO is a better buy in the long-term than SLRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHIO’s TA Score shows that 5 TA indicator(s) are bullish while SLRX’s TA Score has 4 bullish TA indicator(s).

  • PHIO’s TA Score: 5 bullish, 5 bearish.
  • SLRX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SLRX is a better buy in the short-term than PHIO.

Price Growth

PHIO (@Biotechnology) experienced а -24.07% price change this week, while SLRX (@Biotechnology) price change was +7.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

PHIO is expected to report earnings on Mar 31, 2025.

SLRX is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHIO($12M) has a higher market cap than SLRX($1.14M). PHIO YTD gains are higher at: 13.889 vs. SLRX (-60.870). SLRX has higher annual earnings (EBITDA): -5.21M vs. PHIO (-7.41M). PHIO has more cash in the bank: 5.39M vs. SLRX (3.28M). PHIO has less debt than SLRX: PHIO (0) vs SLRX (329K). PHIO (0) and SLRX (0) have equivalent revenues.
PHIOSLRXPHIO / SLRX
Capitalization12M1.14M1,054%
EBITDA-7.41M-5.21M142%
Gain YTD13.889-60.870-23%
P/E Ratio0.01N/A-
Revenue00-
Total Cash5.39M3.28M164%
Total Debt0329K-
FUNDAMENTALS RATINGS
PHIO vs SLRX: Fundamental Ratings
PHIO
SLRX
OUTLOOK RATING
1..100
404
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
3797
P/E GROWTH RATING
1..100
56100
SEASONALITY SCORE
1..100
5044

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLRX's Valuation (28) in the null industry is somewhat better than the same rating for PHIO (66) in the Biotechnology industry. This means that SLRX’s stock grew somewhat faster than PHIO’s over the last 12 months.

SLRX's Profit vs Risk Rating (100) in the null industry is in the same range as PHIO (100) in the Biotechnology industry. This means that SLRX’s stock grew similarly to PHIO’s over the last 12 months.

SLRX's SMR Rating (96) in the null industry is in the same range as PHIO (96) in the Biotechnology industry. This means that SLRX’s stock grew similarly to PHIO’s over the last 12 months.

PHIO's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for SLRX (97) in the null industry. This means that PHIO’s stock grew somewhat faster than SLRX’s over the last 12 months.

PHIO's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for SLRX (100) in the null industry. This means that PHIO’s stock grew somewhat faster than SLRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PHIOSLRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 24 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SG18.451.28
+7.45%
Sweetgreen
RTC0.200.01
+2.57%
Baijiayun Group Ltd
HDSN5.310.03
+0.57%
Hudson Technologies
VLYPO23.830.02
+0.08%
Valley National Bancorp
QGEN42.32-0.02
-0.05%
Qiagen N.V.

PHIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHIO has been loosely correlated with MTNB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PHIO jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHIO
1D Price
Change %
PHIO100%
-18.33%
MTNB - PHIO
50%
Loosely correlated
-2.48%
TPST - PHIO
49%
Loosely correlated
+4.09%
BPMC - PHIO
40%
Loosely correlated
+2.81%
IMNN - PHIO
39%
Loosely correlated
-1.34%
SAGE - PHIO
38%
Loosely correlated
-0.78%
More

SLRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLRX has been closely correlated with MBIO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if SLRX jumps, then MBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLRX
1D Price
Change %
SLRX100%
+9.26%
MBIO - SLRX
71%
Closely correlated
+7.21%
AZTR - SLRX
39%
Loosely correlated
+3.87%
PHIO - SLRX
37%
Loosely correlated
-18.33%
NRSN - SLRX
32%
Poorly correlated
-2.28%
PBM - SLRX
30%
Poorly correlated
+4.05%
More